ArticleRadiation oncology journal2026
A retrospective analysis for early-stage non-endometrioid endometrial cancers.
Article in Radiation oncology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to investigate treatment outcomes and explore optimal adjuvant treatment options for patients with early-stage uterine serous carcinoma (USC) and clear cell carcinoma (CCC). MATERIALS AND
methodsWe retrospectively reviewed the records of 63 patients diagnosed with stage I-II (2009 International Federation of Gynecology and Obstetrics [FIGO]) USC or CCC. Survival outcomes were estimated using the Kaplan-Meier method, and comparisons between groups were performed with the log-rank test.
resultsAmong the 63 patients, 36 (57.1%) had USC and 25 (39.7%) had CCC. According to the revised 2023 FIGO staging system, 23 patients (36.5%) were stage IC, and 40 (63.5%) were stage IIC. Adjuvant treatment included no adjuvant therapy (23.8%), chemotherapy alone (39.7%), radiotherapy alone (28.6%), and combined chemotherapy plus radiotherapy (8.0%). After a median follow-up of 54 months (range, 5 to 227 months), the 5-year progression-free survival (PFS) and overall survival (OS) for the entire cohort were 89.5% and 85.7%, respectively. Patients with CCC had a 5-year PFS of 95.8% and OS of 92.3%, whereas those with USC had a 5-year PFS of 85.1% and OS of 81.4%. Most recurrences (7/63, 11.1%) were distant, occurring predominantly in USC cases (6/7) and 2023 stage IIC (7/7).
conclusionIn this retrospective study, early-stage USC and CCC had very favorable PFS and survival outcomes. Thus, future randomized clinical trial or large cohort study is necessary to determine the optimal adjuvant treatments in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.